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Abstract
Background: Macrolide resistant Streptococcus pneumoniae has been on a gradual increase in Germany for over a
decade. The current study was undertaken against the background of the recent observation of declining
macrolide resistance rates especially among German children. Nationwide surveillance of invasive pneumococcal
disease has been conducted in Germany since 1992. A population- and laboratory-based approach was used to
collect data on invasive pneumococcal disease, and isolates sent to the National Reference Center for Streptococci
by diagnostic microbiological laboratories from 1992 to 2008 were included in this study.
Results: From 1992 to 2008, data on macrolide susceptibility were available for 11,807 invasive isolates. 8,834
isolates (74.8%) were from adults (≥ 16 years), and 2,973 isolates (25.2%) from children (< 16 years). The overall
nonsusceptibility rate of all isolates was 16.2% (intermediate, 0.2%; resistant, 16.0%). Higher resistance rates were
observed among children (intermediate, 0.2%; resistant, 23.8%) than among adults (intermediate, 0.3%; resistant
13.4%). Maximum nonsusceptibility rates during the period under study were observed in 2005 (children:
intermediate, 0.3%; resistant, 32.3%; adults: intermediate, 0.0%; resistant, 18.6%), while nonsusceptibility rates in 2008
were considerably lower, especially for children (children: intermediate, 0.0%; resistant, 15.2%; adults: intermediate,
0.1%; resistant, 12.9%). The rate of resistance was higher among the vaccine serotypes (7-valent, 36.6%; 10-valent,
28.2%; 13-valent, 24.3%) than among the non vaccine serotypes (non 7-valent, 6.5%; non 10-valent, 7.4%; non
13-valent, 6.3%). Serotype 14 (69.6% nonsusceptibility) proved to be the most resistant serotype.
Conclusions: There has been a considerable and statistically significant decrease in macrolide nonsusceptibility in
Germany since 2005, especially among children.
Background
Streptococcus pneumoniae is a leading pathogen in
bacterial pneumonia, sepsis and meningitis in humans
worldwide [1,2]. In many European countries the rate of
resistance of S. pneumoniae to macrolides has exceeded
that of penicillin [3]. Concerning penicillin, it has been
described that treatment of patients with nonmeningeal
invasive pneumococcal infections with nonsusceptible iso-
lates was not associated with higher mortality rates [4-6].
In 2008 new penicillin breakpoints for S. pneumoniae
were published by the CLSI [7], differentiating meningitis
and non-meningitis cases of invasive pneumococcal dis-
ease (IPD). Their impact on susceptibility categorisation
in Germany was described previously by our group [8].
However, for macrolides an increased risk of macrolide
failure has been reported for pneumococcal isolates non-
susceptible in vitro [9].
The aim of this study was to evaluate macrolide sus-
ceptibility of all isolates of S. pneumoniae with IPD that
were sent to the German National Reference Center for
Streptococci (NRCS) between 1992 and 2008 and to
evaluate potential trends in nonsusceptibility over time.
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The study was undertaken against the background of
the recent observation of declining macrolide resistance
rates especially among German children.
Methods
Study design
The NRCS has conducted surveillance for invasive pneu-
mococcal disease in Germany since 1992. A population-
and laboratory-based approach was used to collect data on
invasive pneumococcal disease among children < 16 years
and adults ≥ 16 years in Germany. Isolates were sent to
t h eN R C Sb yd i a g n o s t i cm i c r o b i o l o g i c a ll a b o r a t o r i e s
throughout Germany on a voluntary basis. Cases from
January 1, 1992 to December 31, 2008 were included in
this study. A case of IPD was defined by the isolation of
S. pneumoniae from a normally sterile site.
Microbiological investigations
Isolates were identified by standard procedures includ-
ing bile solubility and optochin sensitivity. Minimal inhi-
bitory concentrations (MIC) testing was performed
using the broth microdilution method as recommended
by the Clinical and Laboratory Standards Institute
(CLSI) [7]. Macrolide resistance was investigated using
erythromycin or clarithromycin, in which testing with
erythromycin was replaced by clarithromycin over the
years. 425 isolates were tested both for erythromycin
and clarithromycin. The susceptible, intermediate, and
resistant breakpoints (MIC) were ≤ 0.25, 0.5, and ≥1 μg/
ml, both for erythromycin and clarithromycin [7]. Strep-
tococcus pneumoniae ATCC 49619 was used as a con-
trol strain.
Statistical analysis
All categorical data were expressed as frequencies. To
analyse a severe increase or decrease over time the
Cochran-Armitage test was used. The overall signifi-
cance level was adjusted using the Bonferroni correction
to account for the problem of multiple testing. Due to
14 tests p-values ≤ 0.0036 were considered as statisti-
cally significant test results. All statistical analyses were
conducted using SAS Version 9.1.3 (SAS Institute Inc.,
Cary, NC, USA).
Results
In total, 12,136 isolates from invasive pneumococcal dis-
ease were collected between January 1, 1992 and
December 31, 2008. The number of cases for each year
vary between 297 and 2,037 (median: 505 cases). Data
on macrolide susceptibility were available for 11,807 iso-
lates, whereas 8,834 isolates (74.8%) originated from
adults, 2,973 isolates (25.2%) were from children.
The overall nonsusceptibility rate of all isolates was
16.2% (intermediate, 0.2%; resistant, 16.0%). Higher
resistance rates were observed among children (inter-
mediate, 0.2%; resistant, 23.8%) than among adults
(intermediate, 0.3%; resistant 13.4%) (Table 1).
The sampling source related nonsusceptibility is
s h o w ni nT a b l e2 .H i g h e s tn o n susceptibility rates were
observed for pharyngeal isolates (75%, n = 4), pericar-
dium (50%, n = 8) and mastoid (40%, n = 10). Nonsus-
ceptibility rates for CSF and blood were 17.8% (n =
1824) and 15.9% (n = 9352), respectively. The serotype
distribution broken down to the sampling source is
shown in Table 3. For blood, CSF and BAL serotype 14
is most prevalent, whereas for pleural fluid serotypes 1
and 3 are most often found.
As for the childhood IPD isolates in the first year of this
study (1992), 2.0% were intermediate and 10.0% resistant
to macrolides. Maximum nonsusceptibility rates during
the period under study were observed in 2005 (intermedi-
ate, 0.3%; resistant, 32.3%), while in 2008, 0.0% of isolates
were intermediate and 15.2% resistant. IPD isolates
obtained from adults were intermediate in 0.0% and resis-
tant in 2.9% in 1992. Maximum nonsusceptibility rates
were observed in 2005 as well (intermediate, 0.0%; resis-
tant, 18.6%). Nonsusceptibility rates in 2008 were 0.1%
(intermediate) and 12.9% (resistant). The increase in
macrolide nonsusceptibility from 1992 to 2005 was statis-
tically significant for children (P < 0.0001) and adults (P <
0.0001), as well as the decrease from 2005 to 2008 (chil-
dren, P < 0.0001; adults, P < 0.0001). Concerning the inter-
mediate resistant isolates no significant trends were
observed (1992-2005: children (P = 0.8942), adults (P =
0.4302); 2005-2008: children (P = 0.6282), adults (P =
0.5960)). Detailed results of the macrolide susceptibility
testing are shown in Figure 1. The MICs of all invasive iso-
lates are illustrated in Figure 2.
Overall, the leading serotypes were serotypes 14
(16.4% of serotyped isolates), 3 (8.1%), 7F (7.6%), 1
(7.3%) and 23F (5.9%). A ranking of serotype specific
macrolide nonsusceptibility of IPD isolates is shown in
Table 1. Serotype 14 (69.5% nonsusceptibility) was by
far the most resistant serotype, followed by serotypes
rough, 19B, 45 (33.3% each), 6B (32.9%), 15A (31.3%),
19F (26.1%), and 19A (25.5%). However, absolute num-
bers for rough, 19B and 45 were very low.
Serotypes contributing considerably to pneumococcal
macrolide nonsusceptibility by combination of frequency
among invasive isolates and relatively high macrolide non-
susceptibility are especially serotypes 14, 6B, 19F, 19A, 9V
and 23F. The development of nonsusceptibility of these
serotypes over the years is shown in Figure 3. The nonsus-
ceptibility among serotype 14 isolates increases consider-
ably over the years up to around 80% (P < 0.0001).
For serotype 19F a significant increase (P = 0.0033) in
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Page 2 of 9Table 1 Ranking of serotype specific macrolide nonsusceptibility among IPD isolates in Germany from 1992 to 2008
(n, overall = 11,807; n, adults = 8,834; n, children = 2,973)
children adults overall
Sero
type
I% R% S% total
(n)
I% R% S% total
(n)
I% R% S% total
†
(n)
total
‡
(%)
14 0.0 67.4 32.6 663 0.2 71.0 28.8 883 0.1 69.5 30.4 1546 16.4
45 - - - - 0.0 33.3 66.7 3 0.0 33.3 66.7 3 0.0
19B 0.0 0.0 100.0 1 0.0 50.0 50.0 2 0.0 33.3 66.7 3 0.0
rough 0.0 25.0 75.0 8 0.0 40.0 60.0 10 0.0 33.3 66.7 18 0.2
6B 0.0 29.3 70.7 215 0.4 36.2 63.4 232 0.2 32.9 66.9 447 4.8
15A 4.8 28.6 66.7 21 0.0 33.3 66.7 27 2.1 31.3 66.7 48 0.5
19F 0.0 24.5 75.5 212 0.4 27.5 72.0 236 0.2 26.1 73.7 448 4.8
19A 0.0 24.4 75.6 90 0.9 26.0 73.2 231 0.6 25.5 73.8 321 3.4
10B - - - - 0.0 20.0 80.0 10 0.0 20.0 80.0 10 0.1
19C 0.0 0.0 100.0 2 0.0 33.3 66.7 3 0.0 20.0 80.0 5 0.1
15B 0.0 23.1 76.9 26 0.0 17.5 82.5 57 0.0 19.3 80.7 83 0.9
23F 0.5 20.4 79.1 201 0.6 18.3 81.2 356 0.5 19.0 80.4 557 5.9
9V 0.9 13.2 85.8 106 1.3 20.1 78.5 298 1.2 18.3 80.4 404 4.3
NT 0.0 10.0 90.0 10 0.0 20.7 79.3 29 0.0 17.9 82.1 39 0.4
11F - - - - 0.0 16.7 83.3 6 0.0 16.7 83.3 6 0.1
15C 0.0 15.4 84.6 26 0.0 14.8 85.2 27 0.0 15.1 84.9 53 0.6
9A 0.0 9.5 90.5 21 0.0 19.2 80.8 26 0.0 14.9 85.1 47 0.5
33B 0.0 0.0 100.0 3 0.0 25.0 75.0 4 0.0 14.3 85.7 7 0.1
33A 0.0 11.1 88.9 9 0.0 14.3 85.7 21 0.0 13.3 86.7 30 0.3
33F 0.0 0.0 100.0 17 0.0 17.6 82.4 51 0.0 13.2 86.8 68 0.7
12B 0.0 0.0 100.0 3 0.0 20.0 80.0 5 0.0 12.5 87.5 8 0.1
6A 0.0 5.5 94.5 128 0.4 9.7 89.9 277 0.2 8.4 91.4 405 4.3
28A 0.0 0.0 100.0 4 0.0 12.5 87.5 8 0.0 8.3 91.7 12 0.1
35F 0.0 10.0 90.0 10 0.0 7.8 92.2 64 0.0 8.1 91.9 74 0.8
24F 0.0 6.8 93.2 44 0.0 6.9 93.1 72 0.0 6.9 93.1 116 1.2
13 0.0 0.0 100.0 3 0.0 8.3 91.7 12 0.0 6.7 93.3 15 0.2
16F 0.0 0.0 100.0 7 3.7 7.4 88.9 27 2.9 5.9 91.2 34 0.4
17F 0.0 12.5 87.5 8 0.0 3.2 96.8 31 0.0 5.1 94.9 39 0.4
38 0.0 0.0 100.0 23 0.0 7.9 92.1 38 0.0 4.9 95.1 61 0.6
34 0.0 16.7 83.3 6 0.0 0.0 100.0 15 0.0 4.8 95.2 21 0.2
9N 0.0 0.0 100.0 25 0.0 5.5 94.5 145 0.0 4.7 95.3 170 1.8
11A 0.0 0.0 100.0 15 0.0 5.2 94.8 135 0.0 4.7 95.3 150 1.6
18A 0.0 0.0 100.0 10 0.0 8.3 91.7 12 0.0 4.5 95.5 22 0.2
1 0.4 5.2 94.4 232 0.2 3.5 96.3 458 0.3 4.1 95.7 690 7.3
7F 0.0 3.9 96.1 203 0.4 3.7 95.9 515 0.3 3.8 96.0 718 7.6
5 0.0 0.0 100.0 19 0.0 5.4 94.6 37 0.0 3.6 96.4 56 0.6
10A 0.0 4.0 96.0 50 0.0 2.5 97.5 122 0.0 2.9 97.1 172 1.8
4 0.0 2.9 97.1 102 0.0 2.2 97.8 409 0.0 2.3 97.7 511 5.4
20 0.0 0.0 100.0 5 0.0 2.6 97.4 38 0.0 2.3 97.7 43 0.5
18C 0.6 1.7 97.8 181 0.0 2.8 97.2 145 0.3 2.1 97.5 326 3.5
3 0.0 3.1 96.9 96 0.2 1.8 98.0 663 0.1 2.0 97.9 759 8.1
12F 0.0 0.0 100.0 16 0.0 1.9 98.1 105 0.0 1.7 98.3 121 1.3
8 0.0 0.0 100.0 18 0.5 1.6 97.9 190 0.5 1.4 98.1 208 2.2
23A 0.0 0.0 100.0 14 0.0 1.4 98.6 74 0.0 1.1 98.9 88 0.9
22F 0.0 0.0 100.0 20 0.5 0.5 98.9 186 0.5 0.5 99.0 206 2.2
2 0.0 0.0 100.0 1 0.0 0.0 100.0 11 0.0 0.0 100.0 12 0.1
31 0.0 0.0 100.0 1 0.0 0.0 100.0 25 0.0 0.0 100.0 26 0.3
12A 0.0 0.0 100.0 3 0.0 0.0 100.0 9 0.0 0.0 100.0 12 0.1
18F 0.0 0.0 100.0 5 0.0 0.0 100.0 10 0.0 0.0 100.0 15 0.2
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trends were found for serotypes 6B (P = 0.0040), 9V (P =
0.3554), 19A (P = 0.0740) and 23F (P = 0.0529).
The peak in nonsusceptibility among 7-, 10- and 13-
valent serotypes in adults from 1998 to 2002 (Figure 4)
correlates to an increased incidence of serotype 14 dur-
ing that time [10]. Generally, the rate of resistance is
higher among the vaccine serotypes (7v, 36.6%; 10v,
28.2%; 13v, 24.3%) (Figure 4) than among the non vac-
cine serotypes (non 7v, 6.5%; non 10v, 7.4%; non 13v,
6.3%) (Figure 5). The proportion of nonsusceptible
7-valent vaccine serotypes remained largely constant
from 2000 to 2007 among children (Figure 4). Among
the non PCV7 serotypes the rate of nonsusceptibility is
lower (Figure 5). Concerning adults, an increase of iso-
lates sent to the NRCS can be noticed (Figures 4 and 5).
The fraction of nonsusceptible isolates has declined
Table 1 Ranking of serotype specific macrolide nonsusceptibility among IPD isolates in Germany from 1992 to 2008
(n, overall = 11,807; n, adults = 8,834; n, children = 2,973) (Continued)
23B 0.0 0.0 100.0 6 0.0 0.0 100.0 11 0.0 0.0 100.0 17 0.2
35B 0.0 0.0 100.0 3 0.0 0.0 100.0 8 0.0 0.0 100.0 11 0.1
9L 0.0 0.0 100.0 5 0.0 0.0 100.0 12 0.0 0.0 100.0 17 0.2
Others* 0.0 0.0 100.0 31 0.0 0.0 100.0 62 0.0 0.0 100.0 93 1.0
not serotyped 0.0 4.4 95.6 45 0.2 0.0 99.8 2360 0.2 0.1 99.8 2405 -
total (%) 0.2 23.8 76.1 - 0.3 13.4 86.3 - 0.2 16.0 83.7 - 100.0
total (n) 5 707 2261 2973 24 1184 7626 8834 29 1891 9887 11807 9402
I%, intermediate isolates in percent; R%, resistant isolates in percent; S%, susceptible isolates in percent; n, number of isolates tested.
Total (n)
† represents the number of isolates collected from both children and adults. Total (%)
‡ represents the serotype distribution in percent in relation to the
number of 9402 IPD isolates serotyped.
Others* includes the serotypes (number of isolates, overall): 15F (9), 18B (9), 7C (8), 10F (6), 11B (6), 35A (6), 29 (5), 21 (4), 24A (4), 28F (4), 35C (4), 37 (4), 22A (3),
36 (3), 7A (3), 24B (2), 25F (2), 39 (2), 48 (2), 7B (2), 17A (1), 18 (1), 19 (1), 35 (1), 9 (1).
Table 2 Ranking of macrolide nonsusceptibility among
IPD isolates in Germany from 1992 to 2008 related to
the sampling source (n = 11,807)
Sampling source I% R% I+R% total
(n)
Pharynx 0.0 75.0 75.0 4
Pericard 0.0 50.0 50.0 8
Mastoid 0.0 40.0 40.0 10
BAL 0.6 18.7 19.4 154
Others/unknown 0.0 18.3 18.3 131
CSF 0.2 17.7 17.8 1824
Blood 0.3 15.6 15.9 9352
Pleural fluid 0.4 14.7 15.1 252
Eye 0.0 11.1 11.1 9
Ascites 0.0 8.7 8.7 23
Joint 0.0 5.6 5.6 36
Ear 0.0 0.0 0.0 4
Total 0.3 16.0 16.3 11807
Table 3 Serotype distribution among IPD isolates from
different sampling sites in Germany from 1992 to 2008
in percent (n = 11,807)
Sero
type
Ascites BAL Blood CSF Joint Pleural
fluid
Total
(%)
Total
(n)
14 9,1 10,7 17,4 14,8 0,0 11,0 16,5 1546
3 0,0 6,0 8,6 5,7 3,0 13,8 8,1 759
7F 4,5 1,2 8,0 7,2 0,0 7,2 7,7 718
1 4,5 6,0 8,3 2,6 12,1 15,5 7,4 690
23F 4,5 8,3 5,7 7,1 3,0 6,6 5,9 557
4 4,5 7,1 6,0 3,8 6,1 3,9 5,5 511
19F 9,1 7,1 4,2 6,8 3,0 3,9 4,8 448
6B 9,1 6,0 4,3 6,6 12,1 4,4 4,8 447
6A 4,5 2,4 4,0 5,7 12,1 4,4 4,3 405
9V 0,0 4,8 4,8 2,3 6,1 2,8 4,3 404
18C 4,5 3,6 2,8 5,8 9,1 3,3 3,5 326
19A 4,5 4,8 3,5 2,7 3,0 1,7 3,4 321
8 9,1 1,2 2,4 2,0 0,0 0,6 2,2 208
22F 0,0 0,0 2,3 2,0 6,1 0,6 2,2 206
10A 4,5 1,2 1,6 2,7 3,0 1,7 1,8 172
9N 0,0 2,4 1,9 1,7 0,0 1,1 1,8 170
11A 0,0 1,2 1,6 1,7 0,0 2,8 1,6 150
12F 4,5 2,4 1,3 1,2 0,0 0,6 1,3 121
24F 0,0 0,0 1,2 1,6 0,0 0,6 1,2 116
23A 0,0 1,2 0,8 1,2 0,0 2,8 0,9 88
15B 0,0 0,0 0,7 1,5 3,0 1,7 0,9 83
35F 4,5 0,0 0,7 1,0 0,0 1,7 0,8 74
33F 0,0 1,2 0,6 1,2 3,0 0,6 0,7 68
38 0,0 0,0 0,6 0,8 0,0 0,0 0,7 61
5 0,0 0,0 0,7 0,3 0,0 0,6 0,6 56
15C 4,5 1,2 0,5 0,7 3,0 0,0 0,6 53
15A 0,0 0,0 0,5 0,7 0,0 1,1 0,5 48
9A 0,0 1,2 0,5 0,4 0,0 1,1 0,5 47
20 0,0 0,0 0,4 0,5 0,0 1,1 0,5 43
17F 4,5 3,6 0,3 0,6 0,0 0,0 0,4 39
NT 0,0 2,4 0,4 0,3 3,0 0,0 0,4 39
16F 0,0 0,0 0,3 0,6 0,0 0,6 0,4 34
33A 0,0 0,0 0,3 0,4 0,0 0,6 0,3 30
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after a notable increase from 1992 to 1999 (Figure 4).
Discussion and conclusions
This paper presents the results of 17 years of surveil-
lance for macrolide susceptibility of invasive pneumo-
coccal disease in Germany. The prevalence of
antibiotic-resistant S. pneumoniae continues to increase
worldwide but varies widely between countries [11-13].
In Europe, high resistance rates for macrolides have
been reported from France, Spain, Italy and Belgium
[12,13]. Pneumococcal macrolide resistance rates
reported from Germany were low [12-17]. Nevertheless,
a continuous and statistically significant increase of
macrolide nonsusceptibility could be observed after
publication of these studies, reaching maximum values
in 2005 (children: intermediate, 0.3%; resistant, 32.3%;
adults: intermediate, 0.0%; resistant, 18.6%). The rela-
tively high rate of variation in resistance among child-
hood isolates during the first years of the study is
presumably due to the low number of cases, and a sus-
pected bias for resistant isolates among the centers
sending the isolates. Since 2005, a considerable and sta-
tistically significant decrease especially for childhood
nonsusceptibility has been noticed. These data are simi-
lar to those recently reported from Spain, where a
reduction of erythromycin nonsusceptibility from 42.9%
in 2003 to 20.0% in 2007 has been described [18].
Table 3 Serotype distribution among IPD isolates from
different sampling sites in Germany from 1992 to 2008
in percent (n = 11,807) (Continued)
31 0,0 2,4 0,3 0,2 0,0 0,0 0,3 26
18A 0,0 0,0 0,2 0,4 3,0 0,0 0,2 22
34 0,0 0,0 0,1 0,6 0,0 0,6 0,2 21
Others* 9,1 10,7 2,3 4,5 6,1 1,7 2,8 264
Total 100,0 100,0 100,0 100,0 100,0 100,0 100,0 9371
not
serotyped
4,3 45,5 23,8 2,1 8,3 28,2 20,6 2436
Only sampling sites with ≥ 20 isolates were included in this table.
NT: nontypeable; n: number of isolates tested.
Others* includes the serotypes (number of isolates): rough (18), 9L (17), 23B
(17), 13 (15), 18F (15), 12A (12), 2 (12), 28A (12), 35B (11), 10B (10), 15F (9),
18B (9), 12B (8), 33B (7), 7C (6), 10F (6), 11B (6), 11F (6), 35A (6), 7A (5), 19C
(5), 29 (5), 21 (4), 24A (4), 28F (4), 35C (4), 37 (4), 19B (3), 22A (3), 36 (3), 45
(3), 7B (2), 24B (2), 25F (2), 39 (2), 48 (2), 9(1), 17A (1), 18 (1), 19 (1), 35 (1).
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n, children 50 34 27 22 25 161 162 187 206 236 256 243 264 316 281 273 230
n, adults 450 400 289 282 230 139 192 213 203 428 426 541 386 597 627 1636 1795
children I% 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.3 0.0 0.4 0.0
children R% 10.0 14.7 7.4 27.3 8.0 10.6 14.2 17.6 26.7 25.8 26.2 32.1 28.8 32.3 29.9 20.5 15.2
adults I% 0.0 0.3 0.0 0.0 0.0 0.7 1.0 0.0 0.0 0.0 0.2 0.2 0.8 0.0 0.0 0.8 0.1
adults R% 2.9 3.8 4.5 7.4 8.3 11.5 13.5 16.4 16.3 15.0 13.8 16.5 16.8 18.6 17.5 16.1 12.9
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Figure 1 Macrolide nonsusceptibilities of IPD isolates in Germany. Macrolide nonsusceptibilities of IPD isolates in Germany (1992 to 2008; n,
total = 11,807; n, adults = 8,834; n, children = 2,973; I%, intermediate in percent; R%, resistant in percent; n, number of cases).
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Figure 2 Minimum inhibitory concentrations (MICs) of invasive
isolates. Minimum inhibitory concentrations (MICs) of invasive
isolates (1992-2008, n = 11,807).
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Page 5 of 9An increased awareness of IPD among adults has been
observed since 2007. This correlates to the general
recommendation of pneumococcal conjugate vaccination
for children < 2 years in Germany at the end of July
2006 and an increased interest in serotype information
of IPD. Furthermore, in January 2007 an internet based
laboratory sentinel system (’PneumoWeb’)w a se s t a b -
lished in Germany, which enables participating labora-
tories to transfer anonymised basic patient information
on a voluntary basis. Compared to children, only a
minor reduction of nonsusceptibility has been observed
among adults from 2005 (18.6%) to 2008 (13.0%),
although this reduction was also statistically significant.
Possible reasons for the decrease in macrolide non-
susceptibility include a reduced macrolide consumption
due to the rising resistance rates, as well as the general
recommendation of pneumococcal conjugate vaccination
for children < 2 years in Germany at the end of July
2006. Since the introduction of the vaccine a consider-
able decrease of serotypes included in the 7-valent
pneumococcal conjugate vaccine has been observed
among German children, but also (to a lesser extent)
among adults [10], which is partly due to the association
of serotypes with age [19,20].
The antibiotic prescribing practices, which are thought
to be among the most significant drivers for the spread
Serotype 14 
(P < 0.0001) 
0
20
40
60
80
100
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Years
N
o
n
s
u
s
c
e
p
t
i
b
l
e
 
i
s
o
l
a
t
e
s
 
i
n
 
p
e
r
c
e
n
t
Serotype 19A 
(P = 0.0740) 
0
20
40
60
80
100
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Years
N
o
n
s
u
s
c
e
p
t
i
b
l
e
 
i
s
o
l
a
t
e
s
 
i
n
 
p
e
r
c
e
n
t
Serotype 6B 
(P = 0.0040) 
0
20
40
60
80
100
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Years
N
o
n
s
u
s
c
e
p
t
i
b
l
e
 
i
s
o
l
a
t
e
s
 
i
n
 
p
e
r
c
e
n
t
Serotype 9V 
(P = 0.3554) 
0
20
40
60
80
100
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Years
N
o
n
s
u
s
c
e
p
t
i
b
l
e
 
i
s
o
l
a
t
e
s
 
i
n
 
p
e
r
c
e
n
t
Serotype 19F 
(P = 0.0033) 
0
20
40
60
80
100
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Years
N
o
n
s
u
s
c
e
p
t
i
b
l
e
 
i
s
o
l
a
t
e
s
 
i
n
 
p
e
r
c
e
n
t
Serotype 23F 
(P = 0.0525) 
0
20
40
60
80
100
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Years
N
o
n
s
u
s
c
e
p
t
i
b
l
e
 
i
s
o
l
a
t
e
s
 
i
n
 
p
e
r
c
e
n
t
Figure 3 Serotype specific macrolide nonsusceptibility of IPD isolates in Germany. Serotype specific macrolide nonsusceptibility of IPD
isolates in Germany (1992 to 2008; n, serotype 14 = 1,546; n, serotype 6B = 447; n, serotype 19F = 448; n, serotype 19A = 321; n, serotype 9V =
404; n, serotype 23F = 557).
Imöhl et al. BMC Microbiology 2010, 10:299
http://www.biomedcentral.com/1471-2180/10/299
Page 6 of 9of pneumococcal resistance, differ vastly between
European countries [15,21-23]. A decrease in the use of
macrolides has been reported for instance in Spain [18],
Portugal [24,25], Belgium [26], Slovenia [27] and Taiwan
[28,29]. The influence of a decreased macrolide con-
sumption on macrolide susceptibility is discussed con-
troversially. In Spain a relation between the decrease in
macrolide consumption and the decrease in erythromy-
cin non-susceptibility among children could be shown,
while this effect was absent among the adult population,
probably due to the increase in non-vaccine serotypes
such as 19A (from 3.6% of all invasive serotypes in 2000
to 10.1% in 2007) [18]. Reports from other countries
showed no decrease in macrolide nonsusceptibility fol-
lowing a reduced macrolide consumption [25-29].
Besides the total macrolide consumption, the influence
of long lasting macrolides, which may increase even in
times of decreasing total macrolide consumption [25], is
discussed to be a cause of the macrolide nonsusceptibil-
ity [25,30-32]. Besides antibiotics, pneumococcal conju-
gate vaccination is another important factor associated
with changes in macrolide susceptibility [25,26,33-36].
In our study, high rates of serotype specific resistance
among the more frequent serotypes were observed
among the serotypes 14, 6B, 19F and 23F, in particular.
T h e s er e s u l t sa r ei nl i n ew i t hr e s u l t sf r o mG e r m a n y
p u b l i s h e dp r e v i o u s l yb yt h eN R C Sf o ri n v a s i v e[ 1 4 ]a n d
respiratory tract isolates [37] and comparable to results
reported from several European countries [3,13,38,39].
Notably, a statistically significant trend in increasing
macrolide resistance was seen for serotypes 14 and 19F.
However, since both serotypes are included in the pneu-
mococcal conjugate vaccines, a future reduction of these
serotypes can be expected. The low rate of macrolide
nonsusceptibility among isolates not serotyped corre-
sponds to the fact, that high resistance levels were a
main trigger for initiation of serotyping during the early
years of this study, when consistent serotyping of all iso-
lates was not conducted due to excessive costs.
In spite of all these observations, because the impact of
preventive and therapeutic strategies on pneumococcal
evolution not only depends on, but also influences the
serotype distribution, when normal temporal [11,40] and
regional [15,41,42] variations of serotype distribution are
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% serotyped adults 42.9 18.3 18.3 35.1 35.7 38.8 32.3 44.1 26.6 38.8 52.8 69.7 69.4 98.2 100.0 99.9 100.0
children 7v nonsusceptible % 18.5 20.0 11.1 35.7 14.3 18.8 20.7 25.2 38.0 38.9 39.1 48.3 45.6 45.3 42.5 35.7 38.2
adults 7v nonsusceptible % 9.1 27.8 36.4 39.5 29.4 45.5 50.0 61.2 61.0 59.8 47.4 40.2 37.5 35.3 31.1 33.8 33.6
children 10v nonsusceptible % 17.2 23.5 10.0 33.3 12.5 13.9 17.4 22.0 33.3 32.6 33.3 40.4 36.7 38.2 34.2 24.6 23.5
adults 10v nonsusceptible % 8.0 25.0 33.3 31.3 27.9 38.7 43.8 52.6 59.5 53.1 38.7 32.9 26.8 27.7 24.2 25.2 21.8
children 13v nonsusceptible % 15.8 16.0 9.1 35.3 11.1 13.1 16.0 21.0 30.3 29.9 30.1 36.9 33.9 36.5 32.8 22.0 19.2
adults 13v nonsusceptible % 7.2 22.9 27.3 27.7 28.8 41.0 39.0 43.6 61.2 47.9 32.5 27.6 23.2 23.4 21.3 20.4 17.0
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Figure 4 Macrolide nonsusceptibility among 7-, 10- and 13-valent vaccine serotypes. Macrolide nonsusceptibility among 7-, 10- and 13-
valent vaccine serotypes (IPD isolates in Germany from 1992 to 2008; n, number of cases. Vaccine strains included are: 7-valent: serotypes 4, 6B,
9V, 14, 18C, 19F and 23F; 10-valent: 7-valent serotypes plus 1, 5 and 7F; 13-valent: 10-valent serotypes plus 3, 19A and 6A).
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Page 7 of 9taken into consideration, future developments remain
difficult to predict [32]. Ongoing nationwide surveillance
is necessary to observe further developments of pneumo-
coccal macrolide resistance in Germany.
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